Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.
| Revenue | N/A |
| Net Income | $-221,315,000 |
| Free Cash Flow | $-142,245,000 |
| Book Value / Share | $0.54 |
| Total Liabilities | $46,812,000 |
| Total Equity | $388,748,000 |
| Debt / Equity | 0.02 |
| Current Ratio | 10.15 |
| Interest Coverage | 0.04 |
| Working Capital | $382,021,000 |
Core multiples and valuation signals — useful to compare vs peers.
| P/E (TTM) | -57.95 |
| Industry P/E | N/A |
| Forward P/E | -59.58 |
| P/B | 32.99 |
| Price / Sales | N/A |
| P / FCF | -90.17 |
| EV / EBITDA | -59.80 |
| Graham Number | N/A |
| DCF (placeholder) | — |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Net Margin | N/A |
| ROIC | 0.08% |
| Asset Turnover | N/A |
| RSI (14) | 54.29 |
| SMA 50 | 22.85 |
| SMA 200 | 22.33 |
| MACD | 0.16 |
| Signal | BULLISH |
| Name | Title |
|---|---|
| Mr. Robert W. Duggan | Co-CEO & Executive Chairman (1944) |
| Dr. Mahkam Zanganeh D.D.S., M.B.A. | Co-CEO, President & Director (1970) |
| Mr. Manmeet Singh Soni CPA | COO, CFO & Director (1978) |
| Prof. Dame Kay Davies DBE, FRS CBE | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (1951) |
| Mr. Dave Gancarz | Chief Business & Strategy Officer (—) |
| Dr. Fong Clow | Chief Biometrics Officer (—) |
| Ms. Shelley D. Spray | Chief Education & Brand Officer (1965) |
| Dr. Urte Gayko Ph.D. | Chief Regulatory, Quality & Pharmacovigilance Officer (1971) |
No news available for this company.